RA Capital Management 13F holdings, Q1 2010
Holdings as of March 31, 2010 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 21 US equity positions worth $102.2m in its Q1 2010 13F filing. The largest position was BSTC at 16.7% of the reported book, followed by DEPOMED INC and ARTHROCARE CORP. Against the Q4 2009 filing, it opened 13 new positions, added to 4 and reduced 4 among the top 21 holdings.
What did RA Capital Management own in Q1 2010? Top 21 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2009 |
|---|---|---|---|---|---|---|---|
| 1 | BSTC BIOSPECIFICS TECHNOLOGIES CO | 16.7% | $17.1m | 614,917 | -27% | reduced | |
| 2 | DEPOMED INC | 10.2% | $10.4m | 2,934,697 | – | new | |
| 3 | ARTHROCARE CORP | 9.4% | $9.7m | 324,965 | – | new | |
| 4 | TEVA TEVA PHARMACEUTICAL INDS LTD | Healthcare | 9.1% | $9.3m | 148,191 | – | new |
| 5 | PHARMASSET INC | 8.6% | $8.8m | 329,213 | -6% | reduced | |
| 6 | GILD GILEAD SCIENCES INC | Healthcare | 8.6% | $8.8m | 193,765 | 66% | added |
| 7 | ALXN ALEXION PHARMACEUTICALS INC | 7.8% | $7.9m | 146,128 | – | new | |
| 8 | UTHR UNITED THERAPEUTICS CORP DEL | Healthcare | 7.0% | $7.2m | 129,252 | – | new |
| 9 | LIGAND PHARMACEUTICALS INC | 4.2% | $4.3m | 2,483,690 | 18716% | added | |
| 10 | PSIVIDA CORP | 3.5% | $3.6m | 910,930 | – | new | |
| 11 | AMAG AMAG PHARMACEUTICALS INC | 2.5% | $2.6m | 73,200 | -60% | reduced | |
| 12 | CHINA BIOLOGIC PRODS INC | 2.2% | $2.3m | 206,652 | 1697% | added | |
| 13 | PAR $.02 | 1.8% | $1.8m | 373,940 | – | new | |
| 14 | ANADYS PHARMACEUTICALS INC | 1.7% | $1.7m | 680,200 | – | new | |
| 15 | AASTROM BIOSCIENCES INC | 1.6% | $1.7m | 1,015,202 | – | new | |
| 16 | TELIK INC | 1.4% | $1.4m | 1,712,458 | 261% | added | |
| 17 | IDENIX PHARMACEUTICALS INC | 1.2% | $1.2m | 427,614 | -58% | reduced | |
| 18 | SENOMYX INC | 0.8% | $800.0k | 244,402 | – | new | |
| 19 | RAPTOR PHARMACEUTICAL CORP | 0.8% | $770.0k | 409,709 | – | new | |
| 20 | ENZB ENZO BIOCHEM INC | 0.6% | $618.0k | 102,700 | – | new | |
| 21 | SOMAXON PHARMACEUTICALS INC | 0.2% | $216.0k | 24,993 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.